Exosomal microRNAs as novel diagnostic biomarkers in breast cancer: A systematic evaluation and meta-analysis

• Published in: Asian journal of surgery Vol. 46; no. 11; pp. 4727 - 4736
• Main Authors: Hong, Fangcheng, Li, Ning, Feng, Zheming, Zheng, Yuxin, Zhu, Chunyue, Zhang, Fenghua
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.11.2023; Elsevier
• Subjects: Breast cancer; Exosome; Liquid biopsy; Meta-Analysis; miRNAs; Liquid biopsy; Meta-Analysis; Breast cancer; miRNAs; Exosome
• ISSN: 1015-9584; 0219-3108
• DOI: 10.1016/j.asjsur.2023.05.115

Circulating tumor-derived exosomal microRNAs (miRNAs) play a key role in the development of cancer. We aimed to assess the diagnostic value of circulating exosomal miRNAs in breast cancer (BC). A computer search was conducted for clinical studies on exosomal miRNA diagnosis of breast cancer published in Wanfang, CNKI, China Biology Medicine disc, VIP, Web of Science, Cochrane Library, PubMed, and Embase built up to August 16, 2022. True/false positive (TP/FP) and true/false negative (TN/FN) rates were extracted from each eligible study to obtain pooled sensitivities, specificities, positive/negative likelihood ratios (PLR/NLR), diagnostic odds ratio (DOR), and their 95% confidence intervals (95% CI). The meta-analysis included 7 articles including 348 Asian patients and 260 controls. All miRNAs were quantified using qRT-PCR assays. The sensitivity and specificity of the combination were 0.67 (95% CI = 0.64–0.71) and 0.81 (95% CI = 0.77–0.86), respectively. The combined DOR was 10.2 (95% CI = 6.00–16.74). The combined AUC(area under the subject operating characteristic curve) was 0.83 (0.91–0.96). In conclusion, exosomal-derived miRNA can be a good indicator to improve the diagnosis of breast cancer.